Anti-Obesity Agents on the Horizon
10.21215/kjfp.2025.15.1.2
- Author:
Seung Hee KIM
1
Author Information
1. Department of Family Medicine, Wonkwang University Sanbon Hospital, Wonkwang University School of Medicine, Gunpo, Korea
- Publication Type:Review Article
- From:
Korean Journal of Family Practice
2025;15(1):2-8
- CountryRepublic of Korea
- Language:English
-
Abstract:
Although obesity increases the risks of obesity-related complications and mortality, obesity-related health conditions can be improved through weight loss. If patients with obesity fail to achieve their weight loss goals through lifestyle modifications, obesity pharmacotherapy can be considered.Recently, the field of pharmacological treatments for obesity has developed rapidly, leading to the development of a wide range of anti-obesity agents. In South Korea, representative anti-obesity agents include orlistat, phentermine, phentermine-topiramate, naltrexone-bupropion, and subcutaneous Glucagon-Like Peptide 1 (GLP-1) receptor agonists such as liraglutide and semaglutide. Various anti-obesity agents are emerging, including oral GLP-1 receptor agonists, GLP-1/Glucose-Dependent Insulinotropic Polypeptide (GIP) dual agonists, GLP-1/glucagon dual agonists, GLP-1/GIP/glucagon triple agonists, GLP-1/amylin dual agonists, Peptide YY-based drugs, and other pharmacotherapies not based on enteropancreatic hormones. This review examined the efficacy and safety of currently available and upcoming anti-obesity agents.
